Text Size

Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D


  • 2022
  • Eye (London)
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy. andrea.leonardi@unipd.it; Bichat Hospital and Foundation A. de Rothschild, Paris, France; Department of Biomedical Sciences, Ophthalmology Clinic, University of Messina, Messina, Italy; Santen SAS, Evry, France; Universidad de Sevilla, Seville, Spain; Department of Ophthalmology, Semmelweis University, Budapest, Hungary; Department of Ophthalmology, University Hospital Necker Enfants Malades, APHP, Paris, France; INSERM Unit 1138, T17 Paris Cité University, Paris, France

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.


Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.


Management of inflammation in dry eye disease: Recommendations from a European panel of experts

Messmer EM, Ahmad S, Benitez del Castillo JM, Mrukwa-Kominek E, Rolando M, Vitovska O, Baudouin C, On behalf of a panel of European Dry Eye Disease experts


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022